Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and traditional v ...

Jazz Pharmaceuticals (JAZZ) reported adjusted earnings of $5.30 per share in second-quarter 2024, beating the Zacks Consensus Estimate of $4.68. Earnings rose 18% year over year. Total revenues in the reported quarter rose 7% year over year to $1.02 billion. Sales of Xywav, Epidiolex and Rylaze drove the upside. The reported figure beat the Zacks Consensus Estimate of $1.0 billion. Quarter in Detail Net product sales rose 2% year over year at $964.1 million. The reported figure beat the Zacks Consensus Esti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Market LLC Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 or ☐ Transition report pursuant to Section 1 ...

| --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------|-------|-------|-------|-------|----------| | | | | | | | | | | | | | | | | | | | | | | 2024 Second Quarter | | | | | | | Innovating to Transform the Lives of Patients and Their Families Financial Results | | | | | | | | | | | | | | | | | | | Caroline | Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-lookin ...

Jazz Pharmaceuticals plc. (NASDAQ:JAZZ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Andrea Flynn - Vice President and Head-Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renée Galá - President and Chief Operating Officer Rob Iannone - Executive Vice President and Global Head-R&D Phil Johnson - Executive Vice President and Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Marc Goodman - Leerink Jessica Fye - JPMorg ...

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.30 per share, beating the Zacks Consensus Estimate of $4.68 per share. This compares to earnings of $4.51 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 13.25%. A quarter ago, it was expected that this drugmaker would post earnings of $4.14 per share when it actually produced earnings of $2.68, delivering a surprise of -35.27%. Over the last four quarters, th ...

Exhibit 99.1 Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance – 15% year-over-year revenue increase from combined key growth drivers: Xywav , Epidiolex and Rylaze – – Oncology revenues grew 10% year-over-year – – Zanidatamab granted Priority Review by U.S. FDA for 2L BTC; PDUFA date of November 29, 2024 – – Near-term, late-stage pipeline catalysts anticipated through 2025 – – Narrowing 2024 total revenue guidance to $4.0 to $4.1 billion – – Affirming G ...

– 15% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® – – Oncology revenues grew 10% year-over-year – – Zanidatamab granted Priority Review by U.S. FDA for 2L BTC; PDUFA date of November 29, 2024 – – Near-term, late-stage pipeline catalysts anticipated through 2025 – – Narrowing 2024 total revenue guidance to $4.0 to $4.1 billion – – Affirming GAAP and non-GAAP adjusted net income guidance – DUBLIN, July 31, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasd ...

The biotechnology sector doesn't need to rizz up investors, as the kids like to say. Unless the human desire to find solutions for vexing conditions and diseases somehow goes away in a dystopian paradigm, the ecosystem is safe. I'd venture to say that it's permanently relevant. However, that doesn't necessarily mean you should buy any example of biotech stocks that come your way. However, the sector faces significant risks – it's not the most predictable industry. One bad clinical result can send enterprise ...

This Earnings ESP, combined with its Zacks Rank #4 (Sell), makes it difficult to conclusively predict that Stevanato will beat the consensus EPS estimate. Over the last four quarters, the company surpassed EPS estimates just once. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Jazz doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. ...